Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biol Rep ; 41(5): 2835-44, 2014 May.
Article in English | MEDLINE | ID: mdl-24452720

ABSTRACT

Allelic variation of BAT-25 (a 25-repeat quasimonomorphic poly T) and BAT-26 (a 26-repeat quasimonomorphic polyA) loci as two mononucleotide microsatellite markers, were analyzed with high-performance liquid chromatography (HPLC) compared with Real-Time PCR using hybridization probes. BAT-26 and BAT-25 markers were used to determine an appropriate screening technique with high sensitivity and specificity to diagnose microsatellite instability (MSI) status in patients with colorectal cancer (CRC). One of the pathways in colorectal tumor genesis is microsatellite instability (MSI+). MSI is detected in about 15% of all CRCs; 3% are of these are associated with Lynch syndrome and the other 12% are caused by sporadic. Colorectal tumors with MSI have distinctive features compared with microsatellite stable tumors. Due to the high percentage of MSI+ CRC in Iran, screening of this type of CRC is imperative. Two markers were analyzed in tissues and sera of 44 normal volunteers and tumor and matched normal mucosal tissues as well as sera of 44 patients with sporadic CRC. The sensitivity and specificity of BAT-26 with real time PCR method (Hybridization probe) were 100% in comparison with sequencing method as the gold standard, while HPLC had a lower sensitivity and specificity. According to HPLC data, BAT-26 was more sensitive than BAT-25 in identifying MSI tumors. Therefore, MSI typing using the BAT-26 hybridization probe method compared to HPLC could be considered as an accurate method for diagnosing MSI in CRC tumors but not in serum circulating DNAs.


Subject(s)
Colorectal Neoplasms/genetics , Microsatellite Instability , Microsatellite Repeats , Adult , Aged , Biomarkers, Tumor , Case-Control Studies , Cell Line, Tumor , Chromatography, High Pressure Liquid , Colorectal Neoplasms/pathology , Female , Genetic Markers , Germ-Line Mutation , Humans , Male , Middle Aged , Neoplasm Grading , Neoplasm Staging , Nucleic Acid Hybridization , ROC Curve , Real-Time Polymerase Chain Reaction
2.
Mol Biol Rep ; 40(5): 3851-7, 2013 May.
Article in English | MEDLINE | ID: mdl-23271133

ABSTRACT

Colorectal cancer (CRC) is the third most common cancer worldwide. Colorectal cancer incidence differs widely among different geographic regions. In addition to mutational changes, epigenetic mechanisms also play important roles in the pathogenesis of CRCs. O6-methylguanine-DNA methyltransferase (O(6)-MGMT) is a DNA repair protein and in the absence of MGMT activity, G-to-A transition may accumulate in the specific genes such as K-ras and p53. To identify which CpG sites are critical for its downregulation, we analyzed the methylation status of the MGMT gene promoter in two sites in CRC patients. Then we compared the frequency of their methylation changes with the results of our previously reported K-ras gene mutation, APC2 and p16 methylation. MGMT methylation was examined in 92 tumor samples. A methylation specific PCR (MSP) method was performed for two loci of MGMT gene which described as MGMT-A and MGMT-B. The prevalence of MGMT-A, and MGMT-B methylation was 49/91 (53.8%), and 83/92 (90.2%), respectively. We detected high frequency of MGMT-B but not MGMT-A methylation in tumor tissues with APC2 methylation. Our results showed that MGMT-B methylation is significantly associated with K-ras gene mutation rather than MGMT-A (p = 0.04). Simultaneously, an inverse correlation was found between p16 and MGMT-B methylation simultaneously (p = 0.02). Our study indicated that hypermethylation of the specific locus near the MGMT start codon is critical for cancer progression. MGMT-B assessment that is associated with K-ras mutation can have a prognostic value in patients with CRC.


Subject(s)
Colorectal Neoplasms/genetics , DNA Methylation , O(6)-Methylguanine-DNA Methyltransferase/genetics , Promoter Regions, Genetic , Adult , Aged , Case-Control Studies , Colorectal Neoplasms/pathology , Epigenesis, Genetic , Female , Gene Expression Regulation, Neoplastic , Humans , Male , Middle Aged , Neoplasm Staging
3.
Int J Biol Markers ; 19(4): 305-9, 2004.
Article in English | MEDLINE | ID: mdl-15646837

ABSTRACT

Previous studies have related opium and its pyrolysates to the risk of developing certain cancers. The aim of this work was to evaluate the clinical usefulness of determining carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA) levels in habitual opium smokers. Serum CEA concentrations were measured in 128 opium smokers and in 44 controls of cigarette only smokers and 47 normal non-smokers by an EIA-based assay. TPA levels were also determined in serum and urine of a subgroup in the study population. The results indicated that serum CEA concentrations are higher in opium smokers than in healthy tobacco smokers (p = 0.004) and non-smokers (p = 0.001). The amount of opium used correlated with the serum CEA level (r = 0.276, p < 0.0001). The mean urine and serum TPA levels of the opium-addicted population were also higher than that of the non-smoking control group, but the differences were not statistically significant. We conclude that opium smoking is associated with elevated serum CEA levels. Therefore, for management of opium users with neoplastic diseases, increased levels of serum CEA should be viewed with caution to avoid misdiagnosis.


Subject(s)
Biomarkers, Tumor , Carcinoembryonic Antigen/blood , Opium/pharmacology , Tissue Polypeptide Antigen/biosynthesis , Adult , Aged , Case-Control Studies , Dose-Response Relationship, Drug , Female , Humans , Immunoenzyme Techniques , Male , Middle Aged , Neoplasms/diagnosis , Smoking , Substance-Related Disorders
4.
J Cell Physiol ; 186(1): 124-35, 2001 Jan.
Article in English | MEDLINE | ID: mdl-11147807

ABSTRACT

A mutated yeast cell 22574d lacking all three proline transporters, PUT4, UGA4, and GAP1, and incapable of growth on proline recovers its lost ability to grow on proline as sole nitrogen source when transformed with a mutagenized mouse gamma-actin cDNA (M-gamma-A). Native mouse gamma-actin cDNA is ineffective. The 3'-region of gamma-actin cDNA was mutagenized to resemble E51 cDNA previously isolated from Ehrlich tumor cells. The E51 cDNA has an extended reading frame in the 3'-region compared to that in native gamma-actin. The extension of the open reading frame in E51 cDNA, was found to be due to an additional pair of bases (TG) at position 1104 of E51 cDNA. After site-directed mutagenesis of the 3'-region of native gamma-actin cDNA to resemble that of E51 cDNA, the construct, M-gamma-A cDNA, was expressed in the 22574d yeast. While the transformation with M-gamma-A increased the uptake of both proline and gamma-amino butyric acid, the transport of five other solutes was not changed by this transformation. Northern blotting of the nontransformed and the M-gamma-A-transformed 22574d cells with gene-specific probes for the three proline transporters showed the expression of an mRNA for UGA4 in both transformed and nontransformed cells but no evidence for the expression of GAP1 or PUT4. The mRNA for UGA4 was expressed at a lower level in strain 22574d than in the parent yeast sigma1278b. Furthermore, the message in the mutated cells is smaller in size by about 15%. These results are consistent with the synthesis of a mutated transporter which requires the coexpression of M-gamma-A, but not native gamma-actin, to restore physiological function, i.e., proline or gamma-amino acid transport.


Subject(s)
Actins/genetics , Actins/pharmacology , Carrier Proteins/genetics , Mutation , Yeasts/genetics , Amino Acid Sequence/genetics , Amino Acid Transport Systems , Base Sequence/genetics , Carrier Proteins/metabolism , Cell Division/drug effects , Cell Line, Transformed , Cycloheximide/pharmacology , DNA Transposable Elements , Ions , Molecular Sequence Data , Proline/pharmacology , Protein Synthesis Inhibitors/pharmacology , Quaternary Ammonium Compounds/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Yeasts/cytology , Yeasts/drug effects , Yeasts/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...